Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Heike Pfeifer, MD, Sylvia Wystub, PhD, A. Binckebanck, Barbara Wassmann, Andreas Käbisch, Michael Lübbert, MD, Lothar Leimer, MD, Aristoteles Giagounidis, MD, Winfried Gassmann, MD, PhD, Patrick Brueck, MD, Hubert Serve, Prof. Dr. med., Dieter Hoelzer, MD, Oliver G. Ottmann, MD

Blood (2012) 120 (21): 1503.

https://doi.org/10.1182/blood.V120.21.1503.1503

Published: 2012

Journal Articles

Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.

Blood (2012) 120 (21): 2608.

https://doi.org/10.1182/blood.V120.21.2608.2608

Published: 2012

Journal Articles

Serial Analysis of BCR-ABL Kinase Domain Mutations Prior to and During Imatinib Treatment for Newly Diagnosed and Recurrent BCR-ABL Positive Acute Lymphoblastic Leukemia.

Heike Pfeifer, Sylvia Wystub, Barbara Wassmann, Jaqueline Maier, PhD, Thoralf Lange, MD, Andreas Hochhaus, MD, Dieter Hoelzer, MD, PhD, Oliver Ottmann

Blood (2009) 114 (22): 2041.

https://doi.org/10.1182/blood.V114.22.2041.2041

Published: 2009

Journal Articles

Imatinib and Interferon-Alpha Maintenance Therapy for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

Heike Pfeifer, Barbara Wassmann, Andreas Käbisch, Michael Lübbert, MD, PhD, Lothar Leimer, MD, Aristoteles Giagounidis, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD

Blood (2009) 114 (22): 2042.

https://doi.org/10.1182/blood.V114.22.2042.2042

Published: 2009

Journal Articles

Minimal Residual Disease and Mutational Status Prior to and after SCT for Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Heike Pfeifer, MD, Sylvia Wystub, PhD, Barbara Wassmann, MD, Patrick Brueck, MD, Nicola Goekbuget, MD, Hubert Serve, MD, PhD, Dieter Hoelzer, MD, PhD, Oliver G Ottmann, MD

Blood (2008) 112 (11): 702.

https://doi.org/10.1182/blood.V112.11.702.702

Published: 2008

Journal Articles

Treatment Outcome with Imatinib-Based Maintenance Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

Heike Pfeifer, MD, Barbara Wassmann, MD, Sylvia Wystub, MD, Lydia Wunderle, MD, Joerg Chromik, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Anja Binckebanck, Dieter Hoelzer, MD, Oliver Ottmann, MD

Blood (2007) 110 (11): 2817.

https://doi.org/10.1182/blood.V110.11.2817.2817

Published: 2007

Journal Articles

More Rapid Outgrowth Kinetics of BCR-ABL Mutations in Advanced Versus Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Clinical-Translational Evidence for a Contributory Role of Non-Mutational Resistance Mechanisms.

Heike Pfeifer, MD, Barbara Wassmann, MD, Silvia Wystub, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Hubert Serve, MD, Dieter Hoelzer, MD, Oliver Ottmann, MD

Blood (2007) 110 (11): 10.

https://doi.org/10.1182/blood.V110.11.10.10

Published: 2007

Journal Articles

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Heike Pfeifer, Barbara Wassmann, Anna Pavlova, Lydia Wunderle, Johannes Oldenburg, Anja Binckebanck, Thoralf Lange, Andreas Hochhaus, Silvia Wystub, Patrick Brück, Dieter Hoelzer, Oliver G. Ottmann

Blood (2007) 110 (2): 727–734.

https://doi.org/10.1182/blood-2006-11-052373

Published: 2007

Journal Articles

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Blood (2007) 109 (11): 4686–4692.

https://doi.org/10.1182/blood-2006-11-055186

Published: 2007

Includes: Supplemental data

Journal Articles

Long Term Outcome of Patients with Steroid Refractory Acute Intestinal Graft Versus Host Disease after Treatment with Pentostatin.

Stefan A. Klein, MD, Sabine Mousset, MD, Gesine Bug, MD, Barbara Waßmann, MD, Dieter Hoelzer, MD, Hans Martin, MD

Blood (2006) 108 (11): 2870.

https://doi.org/10.1182/blood.V108.11.2870.2870

Published: 2006

Journal Articles

Sustained Molecular Responses to Dasatanib (SPRYCEL®) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience.

Joerg Chromik, MD, Heike Pfeifer, MD, Lydia Wunderle, MD, Nadine Schoch, Barbara Wassmann, MD, Patrick Brueck, MD, Ashwin Gollerkeri, MD, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD

Blood (2006) 108 (11): 285.

https://doi.org/10.1182/blood.V108.11.285.285

Published: 2006

Journal Articles

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

Heike Pfeifer, MD, Barbara Wassmann, MD, Anna Pavlova, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Dieter Hoelzer, MD, PhD, Oliver Ottmann, MD

Blood (2006) 108 (11): 639.

https://doi.org/10.1182/blood.V108.11.639.639

Published: 2006

Journal Articles

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Blood (2006) 108 (5): 1469–1477.

https://doi.org/10.1182/blood-2005-11-4386

Published: 2006

Journal Articles

A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns.

Heike Pfeifer, MD, Oliver G. Ottmann, MD, Nicola Goekbuget, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Aristoteles Giagounidis, MD, Michael Stelljes, MD, Andreas Hochhaus, MD, Harald Gschaidmeier, MD, Dieter Hoelzer, MD, Barbara Wassmann, MD

Blood (2005) 106 (11): 1824.

https://doi.org/10.1182/blood.V106.11.1824.1824

Published: 2005

Journal Articles

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

Heike Pfeifer, MD, Barbara Wassmann, MD, Anni Pavlova, MD, Martin Mueller, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Johannes Oldenburg, MD, Andreas Hochhaus, MD, Harald Gschaidmeier, MD, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD

Blood (2005) 106 (11): 147.

https://doi.org/10.1182/blood.V106.11.147.147

Published: 2005

Journal Articles

Early molecular response to posttransplantation imatinib determines outcome in MRD + Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Barbara Wassmann, Heike Pfeifer, Michael Stadler, Martin Bornhaüser, Gesine Bug, Urban J. Scheuring, Patrick Brück, Matthias Stelljes, Rainer Schwerdtfeger, Nadezda Basara, Jolanta Perz, Donald Bunjes, Georg Ledderose, Rolf Mahlberg, Anja Binckebanck, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann

Blood (2005) 106 (2): 458–463.

https://doi.org/10.1182/blood-2004-05-1746

Published: 2005

Includes: Supplemental data

Journal Articles

Imatinib Given Concurrently with Induction Chemotherapy Is Superior to Imatinib Subsequent to Induction and Consolidation in Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (PH+ALL).

Oliver G. Ottmann, MD, Barbara Wassmann, MD, Heike Pfeifer, MD, Nicola Goekbuget, MD, Gesine Bug, MD, Patrick Brueck, MD, Anja Binckebanck, Harald Gschaidmeier, MD, Dieter Hoelzer, MD

Blood (2004) 104 (11): 685.

https://doi.org/10.1182/blood.V104.11.685.685

Published: 2004

Journal Articles

Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL).

Dieter Hoelzer, MD, PhD, Nicola Goekbuget, MD, Joachim Beck, MD, Thomas Burmeister, MD, Aristoteles Giagounidis, MD, Axel Glasmacher, MD, Heike Pfeifer, MD, Harald Rieder, MD, Mathias Schmid, MD, Eckhard Thiel, MD, PhD, Barbara Wassmann, MD, Oliver Ottmann, MD, PhD

Blood (2004) 104 (11): 2732.

https://doi.org/10.1182/blood.V104.11.2732.2732

Published: 2004

Journal Articles

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) treated with imatinib

Barbara Wassmann, Heike Pfeifer, Urban J. Scheuring, Anja Binckebanck, Nicola Gökbuget, Johannes Atta, Patrick Brück, Harald Rieder, Claudia Schoch, Lothar Leimer, Rainer Schwerdtfeger, Gerhard Ehninger, Thomas Lipp, Jolanta Perz, Matthias Stelljes, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann

Blood (2004) 103 (4): 1495–1498.

https://doi.org/10.1182/blood-2003-01-0154

Published: 2004

Journal Articles

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph + acute lymphoblastic leukemia

Wolf-Karsten Hofmann, Martina Komor, Barbara Wassmann, Letetia C. Jones, Harald Gschaidmeier, Dieter Hoelzer, H. Phillip Koeffler, Oliver G. Ottmann

Blood (2003) 102 (2): 659–661.

https://doi.org/10.1182/blood-2002-06-1756

Published: 2003

NARROW

Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.

Serial Analysis of BCR-ABL Kinase Domain Mutations Prior to and During Imatinib Treatment for Newly Diagnosed and Recurrent BCR-ABL Positive Acute Lymphoblastic Leukemia.

Imatinib and Interferon-Alpha Maintenance Therapy for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

Minimal Residual Disease and Mutational Status Prior to and after SCT for Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Treatment Outcome with Imatinib-Based Maintenance Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

More Rapid Outgrowth Kinetics of BCR-ABL Mutations in Advanced Versus Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Clinical-Translational Evidence for a Contributory Role of Non-Mutational Resistance Mechanisms.

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Long Term Outcome of Patients with Steroid Refractory Acute Intestinal Graft Versus Host Disease after Treatment with Pentostatin.

Sustained Molecular Responses to Dasatanib (SPRYCEL®) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience.

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns.

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

Early molecular response to posttransplantation imatinib determines outcome in MRD + Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Imatinib Given Concurrently with Induction Chemotherapy Is Superior to Imatinib Subsequent to Induction and Consolidation in Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (PH+ALL).

Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL).

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) treated with imatinib

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph + acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only